ARWR Arrowhead Pharmaceuticals Inc.
Arrowhead Pharmaceuticals, Inc. operates as a biopharmaceutical company. It develops medicines that treat intractable diseases by silencing the genes that cause them. The company was founded by R. Bruce Stewart in 1989 and is headquartered in Pasadena, CA.
Company profile
Ticker
ARWR
Exchange
Website
CEO
Christopher Richard Anzalone
Employees
Incorporated
Location
Fiscal year end
Sector
Industry (SIC)
Former names
ARROWHEAD RESEARCH CORP, INTERACTIVE GROUP INC, INTERACTIVE INC
SEC CIK
Corporate docs
IRS number
460408024
ARWR stock data
()
Investment data
Securities sold
Number of investors
Calendar
23 Nov 20
1 Dec 20
30 Sep 21
News
Financial summary
| Quarter (USD) | Jun 20 | Mar 20 | Dec 19 | Jun 19 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Sep 20 | Sep 19 | Sep 18 | Sep 17 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
Financial data from company earnings reports.
Recent insider trades
| Date | Owner | Security | Transaction | Code | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|
| 20 Nov 20 | Curt Bradshaw | Common Stock | Sell | Dispose S | No | 68.73 | 15,625 | 1.07M | 0 |
| 19 Nov 20 | Martin Javier San | Common Stock | Sell | Dispose S | Yes | 69.39 | 19,500 | 1.35M | 130,500 |
| 19 Nov 20 | Curt Bradshaw | Common Stock | Sell | Dispose S | Yes | 69.39 | 15,625 | 1.08M | 15,625 |
| 9 Nov 20 | Kenneth Allen Myszkowski | Common Stock | Sell | Dispose S | Yes | 69.86 | 17,665 | 1.23M | 427,668 |
| 9 Nov 20 | Kenneth Allen Myszkowski | Common Stock | Sell | Dispose S | Yes | 69.04 | 25,840 | 1.78M | 445,333 |
| 9 Nov 20 | Kenneth Allen Myszkowski | Common Stock | Option exercise | Aquire M | No | 14.54 | 43,505 | 632.56K | 471,173 |
| 9 Nov 20 | Kenneth Allen Myszkowski | Stock Option Common Stock | Option exercise | Dispose M | No | 14.54 | 43,505 | 632.56K | 0 |
| 23 Oct 20 | Anzalone Christopher Richard | Common Stock | Sell | Dispose S | Yes | 58.57 | 12,272 | 718.77K | 2,505,237 |
| 23 Oct 20 | Anzalone Christopher Richard | Common Stock | Sell | Dispose S | Yes | 58.16 | 87,728 | 5.1M | 2,517,509 |
| 20 Oct 20 | Kenneth Allen Myszkowski | Common Stock | Sell | Dispose S | Yes | 54.04 | 29,166 | 1.58M | 427,668 |
Institutional ownership Q3 2020
65.4% owned by funds/institutions
13F holders |
Current |
|---|---|
| Total holders | 260 |
| Opened positions | 39 |
| Closed positions | 32 |
| Increased positions | 81 |
| Reduced positions | 93 |
13F shares |
Current |
|---|---|
| Total value | 3.54B |
| Total shares | 67.24M |
| Total puts | 631.9K |
| Total calls | 1.05M |
| Total put/call ratio | 0.6 |
Largest owners |
Shares | Value |
|---|---|---|
| BLK Blackrock | 12.56M | $540.85M |
| Vanguard | 9.12M | $392.75M |
| STT State Street | 4.54M | $195.63M |
| IVZ Invesco | 3.28M | $141.38M |
| Johnson & Johnson Innovation - JJDC | 3.26M | $140.41M |
| FMR | 1.89M | $81.52M |
| NTRS Northern Trust | 1.6M | $68.7M |
| First Manhattan | 1.58M | $67.97M |
| Geode Capital Management | 1.53M | $65.81M |
| JPM JPMorgan Chase & Co. | 1.47M | $63.68M |
Financial report summary
?
Content analysis
?
| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
H.S. sophomore Avg
|
|
New words:
adequacy, advice, aggregate, Aid, altogether, Aminotransferase, antitrust, appoint, arbitrage, array, Ascending, ATM, bandwidth, behavior, biosimilar, boost, borrow, borrowing, bribery, CA, cardiometabolic, chain, chance, chapter, childcare, Chinese, cleaning, coaching, competitor, constitute, contact, COPD, coupled, curb, defective, density, dialogue, Diego, distancing, diversion, domestic, economy, EEA, encourage, endeavor, entail, ethical, exempt, exempted, fat, filer, fill, forthcoming, fulltime, furlough, GDPR, geography, grew, group, growing, grown, Halozyme, Harmonization, harmonized, home, hospital, HTA, hybrid, Iceland, ICH, Immunologic, impede, implicit, imprisonment, incremental, inhouse, Inline, INSIGHT, Interfering, interplay, Intrahepatic, irrespective, justification, justified, launch, launched, led, left, lessor, Liechtenstein, MA, magnitude, main, marketplace, mentoring, misleading, movement, multifaceted, mutual, NCA, negotiated, nonclinical, noncumulative, Norway, notification, Olpasiran, onsite, outflow, overhaul, pandemic, pause, paused, payout, PDCO, Pegylated, penalized, percentile, Peripheral, permissibility, PIP, plant, pool, postponed, postponing, precautionary, principle, proceeding, punishable, recession, reclassed, reevaluation, regular, reminiscent, rentable, RMP, routinely, San, SAWP, scarring, schooling, seasoned, shell, shipping, shorter, sick, simultaneously, SmPC, social, societal, Society, spread, strict, sublease, subsidy, supervisory, Takeda, talent, temporarily, timeline, training, transposed, treble, trend, tuition, unasserted, uncapped, unclear, undermine, unfair, uniform, unlimited, WI, widespread, withholding, worn, worsening, Wuhan
Removed:
al, alleging, Article, ATO, attractive, Bernstein, Brexit, cal, calendar, calling, captioned, Central, characterization, Circuit, circumstance, clinic, CMC, County, DC, Dec, derivative, discovering, dismissal, dismissed, district, driver, duty, Eskinazi, fiduciary, formally, functioning, half, harmonised, impaired, injunctive, irrevocable, Jackson, Jan, judgement, largest, LeaseExpiration, leave, live, Los, Mar, matter, Meller, monitored, monthly, narrower, NE, Nov, Oct, OfficeSpace, optimizing, perpetual, powerful, prejudice, prepare, putative, reaching, recoverability, recruit, referencing, refractory, rent, replacing, Room, safely, secondary, Siegel, Singh, stayed, Street, sublicense, subset, Super, Treaty, unspecified, Unz, utilized, vested, vivo, Wang, Washington, Weisman
Financial reports
10-K
2020 FY
Annual report
23 Nov 20
10-Q
2020 Q3
Quarterly report
5 Aug 20
10-Q
2020 Q2
Quarterly report
7 May 20
10-Q
2020 Q1
Quarterly report
5 Feb 20
10-K
2019 FY
Annual report
25 Nov 19
10-Q
2019 Q3
Quarterly report
5 Aug 19
10-Q
2019 Q2
Quarterly report
8 May 19
10-Q
2019 Q1
Quarterly report
7 Feb 19
10-K
2018 FY
Annual report
11 Dec 18
10-Q
2018 Q3
Quarterly report
7 Aug 18
Current reports
8-K
Arrowhead Pharmaceuticals Reports Fiscal 2020 Year End Results
23 Nov 20
8-K
Takeda and Arrowhead Collaborate to Co-Develop and Co-Commercialize ARO-AAT for Alpha-1 Antitrypsin-Associated Liver Disease
9 Oct 20
8-K
Departure of Directors or Certain Officers
8 Sep 20
8-K
Arrowhead Pharmaceuticals Reports Fiscal 2020 Third Quarter Results
5 Aug 20
8-K
Arrowhead Pharmaceuticals Reports Fiscal 2020 Second Quarter Results
7 May 20
8-K
Departure of Directors or Certain Officers
1 May 20
8-K
Entry into a Material Definitive Agreement
19 Mar 20
8-K
Arrowhead Pharmaceuticals Reports Fiscal 2020 First Quarter Results
5 Feb 20
8-K
Departure of Directors or Certain Officers
18 Dec 19
8-K
Entry into a Material Definitive Agreement
6 Dec 19
Registration and prospectus
424B5
Prospectus supplement for primary offering
5 Aug 20
S-8
Registration of securities for employees
22 May 20
424B5
Prospectus supplement for primary offering
5 Dec 19
424B5
Prospectus supplement for primary offering
2 Dec 19
S-3ASR
Automatic shelf registration
2 Dec 19
S-8
Registration of securities for employees
29 Mar 19
S-3ASR
Automatic shelf registration
29 Nov 18
S-8
Registration of securities for employees
22 Mar 18
424B5
Prospectus supplement for primary offering
19 Jan 18
424B5
Prospectus supplement for primary offering
17 Jan 18
Proxies
DEF 14A
Definitive proxy
28 Jan 20
PRE 14A
Preliminary proxy
14 Jan 20
DEFA14A
Additional proxy soliciting materials
25 Jan 19
DEF 14A
Definitive proxy
25 Jan 19
DEF 14A
Definitive proxy
25 Jan 18
DEFA14A
Additional proxy soliciting materials
25 Jan 18
DEF 14A
Definitive proxy
1 Feb 17
DEFA14A
Additional proxy soliciting materials
1 Feb 17
DEF 14A
Definitive proxy
19 Jan 16
DEFA14A
Additional proxy soliciting materials
19 Jan 16
Other
CT ORDER
Confidential treatment order
18 Mar 19
EFFECT
Notice of effectiveness
3 Feb 17
EFFECT
Notice of effectiveness
3 Feb 17
CORRESP
Correspondence with SEC
1 Feb 17
CORRESP
Correspondence with SEC
1 Feb 17
CORRESP
Correspondence with SEC
19 Jan 17
CORRESP
Correspondence with SEC
19 Jan 17
CT ORDER
Confidential treatment order
18 Jan 17
CORRESP
Correspondence with SEC
13 Jan 17
CORRESP
Correspondence with SEC
13 Jan 17
Ownership
4
ARROWHEAD PHARMACEUTICALS / Curt Bradshaw ownership change
23 Nov 20
4
ARROWHEAD PHARMACEUTICALS / Martin Javier San ownership change
20 Nov 20
4
ARROWHEAD PHARMACEUTICALS / Kenneth Allen Myszkowski ownership change
12 Nov 20
3
ARROWHEAD PHARMACEUTICALS / James C Hamilton ownership change
2 Nov 20
4
ARROWHEAD PHARMACEUTICALS / Backer Marianne De ownership change
26 Oct 20
4
ARROWHEAD PHARMACEUTICALS / Christopher Richard Anzalone ownership change
23 Oct 20
4
ARROWHEAD PHARMACEUTICALS / Kenneth Allen Myszkowski ownership change
22 Oct 20
4
ARROWHEAD PHARMACEUTICALS / Mauro Ferrari ownership change
13 Oct 20
3
ARROWHEAD PHARMACEUTICALS / ADEOYE Y OLUKOTUN ownership change
8 Sep 20
4
ARROWHEAD PHARMACEUTICALS / Christopher Richard Anzalone ownership change
14 Aug 20
Patents
APP
Utility
Integrin Ligands and Uses Thereof
26 Nov 20
Inventors: Zhen Li, Xiaokai Li, Erik W. Bush, Rui Zhu, Dongxu Shu, Jonathan Benson, Patrick Shao, Matthew Fowler-Watters
GRANT
Utility
RNAi therapy for hepatitis B virus infection
20 Oct 20
Described are compositions and methods for inhibition of Hepatitis B virus gene expression.
APP
Utility
RNAi Agents And Compositions for Inhibiting Expression of Apolipoprotein C-III (APOC3)
24 Sep 20
The present disclosure relates to RNAi agents, e.g., double stranded RNAi agents, capable of inhibiting Apolipoprotein C-III (also called APOC3, apoC-III, APOC-III, and APO C-III) gene expression, and compositions that include APOC3 RNAi agents.
APP
Utility
RNAi Agents for Inhibiting Expression of Alpha-ENaC And Methods of Use
24 Sep 20
Described are RNAi agents, compositions that include RNAi agents, and methods for inhibition of an alpha-ENaC (SCNN1A) gene.
GRANT
Utility
RNAi agents for Hepatitis B virus infection
22 Sep 20
Described are compositions and methods for inhibition of Hepatitis B virus gene expression.